Histologically Sample Clauses

Histologically or cytologically confirmed pancreatic adenocarcinoma with metastasis, who had obtained a best response of at least stable disease (SD) or a partial response (PR) for a period of 2 months with no further shrinkage of ≥ 30% on scan on their first line of chemotherapy for their advanced metastatic disease. Note: Patients that have had prior chemotherapy as adjuvant or neoadjuvant therapy are permitted. 4. Have a performance status of 0 or 1 on the ECOG performance scale. 5. Able to submit an archival tumor specimen (primary or metastatic site) and a discussion is documented with trial investigator at screening that patient will consider providing tissue from a newly obtained core or excisional biopsy of a tumor lesion at baseline and a second biopsy 9 weeks after starting trial treatment, unless tumor is considered inaccessible or biopsy is otherwise considered not in the patients’ best interest. Participation in this trial is not contingent on patient consenting to optional tumor biopsies.
AutoNDA by SimpleDocs
Histologically or cytologically confirmed pancreatic adenocarcinoma with metastasis, who had obtained a best response of at least stable disease (SD) or a partial response (PR) for a period of 2 months with no further shrinkage of ≥ 30% on scan on their first line of chemotherapy for their advanced metastatic disease.
Histologically the first hallmarks of the disease can be detected by 3 months of age, when Cln7Δex2 mice present with AFSM in the hippocampus, cerebral cortex, cerebellum, thalamus and olfactory bulb (Xxxxxxxxxxxx et al., 2016). SCMAS accumulation has been identified by 3 months of age mainly in neurons of the hippocampus, the Purkinje cell layer and granule cell layer of the cerebellum, layer V and VI of the cerebellar cortex and the thalamus, but not in the granule cell layer of the dentate gyrus (Xxxxxxxxxxxx et al., 2016). SCMAS has also been detected in cardiac muscles, the kidney and the liver in Cln7Δex2 mice. Both saposin D and SCMAS were detected within the accumulated AFSM in Cln7Δex2 mice. By 9 months of age Cln7Δex2 mice displayed brain atrophy of the olfactory bulb, cerebral cortex and cerebellum as measured by MRI scanning (Xxxxxxxxxxxx et al., 2016). At end stage disease, by 10 months of age, the mice did not display loss of Purkinje cells in the cerebellum. Astrocytosis was detected in various brain regions, including the hippocampus, cerebral cortex and thalamus by 5 months of age and became progressively worse over time in Cln7Δex2 mice (Xxxxxxxxxxxx et al., 2016). Subsequent microglial activation was detected by 7 months of age in all brain regions of Cln7Δex2 mice, albeit at a less severe level than the astrocytosis. Levels of cathepsins were significantly increased by 5 months of age in both microglia and neurons, but not astrocytes (Xxxxxxxxxxxx et al., 2016). Cln7Δex2 mice also displayed pronounced degeneration of rod photoreceptor cells, reactive astrocytosis and microglial activation, accumulation of SCMAS and saposin D in the retina, resulting in severe retinal degeneration (Xxxxxxxxx et al., 2016).
Histologically. Xxxxx and unrepaired Drew hand-off, but Xxxxxxx voraciously discasing her dinghies. eonwannlocadABgrceHemouesnitn oRce. sLiodceanltiaaul tTheonriatinecsydAugrirnegeamseenrtvpicdef.bDc ohwounsloinagd rBecsiHdeonutsiainl gagRreeimdeennttiafol r ybeuaildr ingInoter rtehsetilnagndwloaryds ptorouvsideetshedeatdadilsitioanbaolunt aymouerseolifginbtileitryesfot,r adnisdpureteceriepstsolaurteionsttaondaorydotuerpmasy oefatchhe oafgprerievmaceynta.cDt iasncldosbeotahntyhesitpueartsion.aInddobtchereirsiildleegnatilaalctetivniatyncayndagsraeneitmaerynst tiasnodnaerdssugregqeusitrieodn.sEtovablrueaaticnhg btooacordmrpelsepteonthsiisbifloitirems aovf abiclatbelenafrnocmy abgcreheomuseingt itnocolulsdaensdeotiimaendhormesepoandibwilriittiteesnatreenaunsucya.llyEltirgaibnislifteyrrfoerd rgtenainnccuyrraegdrebeymceonntflaictttohfepleovliceileosf tthhaet lanhdolmored.rLeipsrtedsebnytalatiwve, hoorguasninisgatteionnasn,clyenadgerersemanedntstinoryaoguer soewanrcshtrastuagpgreosptieorntytycpaeusseodf tbhye caognrfeliecmt oefntthbinegtws eyeonu theanvaentahkaesyntoewthfisorimnfso.rmFeawtioonp.tPiornivsattoe ehnodusteinngaonrcy

Related to Histologically

  • Animals The Hirer shall ensure that no animals (including birds) except guide dogs are brought into the premises, other than for a special event agreed to by the Village Hall. No animals whatsoever are to enter the kitchen at any time.

  • Screening After you sign and date the consent document, you will begin screening. The purpose of the screening is to find out if you meet all of the requirements to take part in the study. Procedures that will be completed during the study (including screening) are described below. If you do not meet the requirements, you will not be able to take part in the study. The study investigator or study staff will explain why. As part of screening, you must complete all of the items listed below: • Give your race, age, gender, and ethnicity • Give your medical history o You must review and confirm the information in your medical history questionnaire • Give your drug, alcohol, and tobacco use history • Give your past and current medication and treatment history. This includes any over-the-counter or prescription drugs, such as vitamins, dietary supplements, or herbal supplements, taken in the past 28 days • Height and weight will be measured • Physical exam will be done • Electrocardiogram (ECG) will be collected. An ECG measures the electrical activity of the heart • You may be tested for COVID-19 o Blood tests for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C o Blood tests to see how your blood clots ▪ Fibrinogen ▪ PT/INR/aPTT o Blood tests for amylase and lipase (enzymes that help with digestion, Part B only) o Blood tests for a lipid (fats) panel (Part B only) ▪ Total cholesterol ▪ Triglycerides ▪ HDL ▪ Direct HDL o Blood tests to check your thyroid function (Part B and Part C only) ▪ TSH ▪ Free T4 o Urine to test for drugs of abuse (illegal and prescription) o Urine tests to check your albumin/ creatinine ratio o Females who have not had a period for at least 12 months in a row will have a blood hormone test to confirm they cannot have children • The study investigator may decide to do an alcohol breath test • The use of proper birth control will be reviewed (males only) • You will be asked “How do you feel?” HIV, hepatitis B, and hepatitis C will be tested at screening. If anyone is exposed to your blood during the study, you will have these tests done again. If you have a positive test, you cannot be in or remain in the study. HIV is the virus that causes acquired immunodeficiency syndrome (AIDS). If your HIV test is positive, you will be told about the results. It may take weeks or months after being infected with HIV for the test to be positive. The HIV test is not always right. Having certain infections or positive test results may have to be reported to the State Department of Health. This includes results for HIV, hepatitis, and other infections. If you have any questions about what information is required to be reported, please ask the study investigator or study staff. Although this testing is meant to be private, complete privacy cannot be guaranteed. For example, it is possible for a court of law to get health or study records without your permission.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Population The Population shall be defined as all Paid Claims during the 12-month period covered by the Claims Review.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Drugs Possession or use of drugs by the Student, any person present in the residence with the Student, or any person present in the Student’s residence with the permission of the Student during the Student’s absence, are strictly prohibited in any UCF DHRL facility. Prohibited drugs include, but are not limited to: A. any substance, the possession or use of which, regardless of amount, could be found to violate Federal or Florida drug abuse prevention and control laws; B. any prescription medication for which the possessor/user does not have a presently valid medical prescription.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Target Population TREATMENT FOR ADULT (TRA) Target Population

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!